Hodi, F Stephen <br/><br/>
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Sep 2013 
 - 3182-90 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2012.47.7836  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Benzamides--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Chronic Disease<br/>Female<br/>GTP Phosphohydrolases--genetics<br/>Gene Amplification<br/>Humans<br/>Imatinib Mesylate<br/>Male<br/>Melanoma--drug therapy<br/>Membrane Proteins--genetics<br/>Middle Aged<br/>Mucous Membrane--drug effects<br/>Mutation--genetics<br/>Neoplasm Recurrence, Local--drug therapy<br/>Piperazines--therapeutic use<br/>Prognosis<br/>Proto-Oncogene Mas<br/>Proto-Oncogene Proteins c-kit--genetics<br/>Pyrimidines--therapeutic use<br/>Skin Neoplasms--drug therapy<br/>Sunlight<br/>Survival Rate